Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetrathiomolybdate in Wilson Disease
NCT00004339Phase 3
Key facts
- Status
- Completed
- Start
- Jan 1994
- Countries
- 1
- Sponsor
- National Center for Research Resources
- Modality
- Small Molecules
- Drugs
- tetrathiomolybdate
- Conditions
- Wilson disease (WD)
01
Overview
Phase 3, randomised, double-blind trial of tetrathiomolybdate in Wilson disease (WD) (2 arms), sponsored by National Center for Research Resources. Primary endpoint: Neurologic deterioration at 8 weeks. Started Jan 1994; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Tetrathiomolybdate
Tetrathiomolybdate 3 times a day with meals and 3 times a day between meals.
Trientine
Trientine therapy.
03
Endpoints
Primary
Neurologic deterioration
Beyond the preview
Go deeper on NCT00004339.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004339.